TIOTROPIUM TRIAL # 205338

点击翻译按钮获取中文摘要

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. Cystic fibrosis (CF) is an inherited autosomal recessive disease that disrupts ion transport in the respiratory tract, leading to chronic infection, inflammation, and obstruction of the conducting airways. New medications are needed to treat pulmonary obstruction and provide additional benefits to CF patients. This protocol is a multi-center, randomized, double-blind, dose-escalation, placebo-controlled study of tiotropium bromide, a long-acting inhaled anticholinergic bronchodilator, in the treatment of CF lung disease.